Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
KEYTRUDA® Plus Padcev® Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR in Adults with Pulmonary Arterial Hypertension
FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm Larvae
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each with Padcev® , as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center
Stellar AfricaGold Intersects Multiple Gold-Bearing Zones and Confirms Structural Controls at Tichka Est, Morocco - Drilling Resumed on January 30, 2026
